Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:37:00 EST Fri 06 Feb 2026
Enter Symbol
or Name
USA
CA



Q:GALT - GALECTIN THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
GALT - Q0.12.50·3.520.12.80-0.03-1.1473.81,1752,8272.82  2.89  2.677.13  1.1519:56:58Dec 1915 min RT 2¢

Recent Trades - Last 10 of 2827
Time ETExPriceChangeVolume
19:56:58Q3.250.4211
19:54:47Q2.900.0714
16:10:04Q2.80-0.031
16:10:04Q2.80-0.031
16:10:04Q2.80-0.031
16:10:04Q2.80-0.031
16:04:52Q2.80-0.031
16:04:36Q2.80-0.031
16:04:14Q2.80-0.031
16:00:21Q2.80-0.038

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-12-19 08:00U:GALTNews ReleaseGalectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027
2025-11-14 08:00U:GALTNews ReleaseGalectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update
2025-11-10 08:00U:GALTNews ReleaseGalectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting
2025-10-20 08:00U:GALTNews ReleaseGalectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference
2025-10-07 08:00U:GALTNews ReleaseGalectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025
2025-09-02 08:00U:GALTNews ReleaseGalectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
2025-08-14 08:00U:GALTNews ReleaseGalectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update
2025-07-09 08:00U:GALTNews ReleaseGalectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026
2025-06-10 08:56U:GALTNews ReleaseGalectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension
2025-05-15 08:00U:GALTNews ReleaseGalectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update
2025-05-12 08:00U:GALTNews ReleaseGalectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress
2025-04-15 08:00U:GALTNews ReleaseGalectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress
2025-03-31 08:00U:GALTNews ReleaseGalectin Therapeutics Reports 2024 Financial Results and Provides Business Update
2025-02-18 08:00U:GALTNews ReleaseGalectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial